News | Structural Heart | March 31, 2023

Abbott Receives FDA Approval for Epic Max Tissue Valve to Treat Aortic Valve Disease

The new valve is designed to preserve and facilitate future patient options for lifetime management of their heart valve disease

The new valve is designed to preserve and facilitate future patient options for lifetime management of their heart valve disease

March 31, 2023 — Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the company's Epic Max stented tissue valve to treat people with aortic regurgitation or stenosis. This device is the latest addition to Abbott's Epic surgical valve platform which has a decades-long history of safety and strong clinical outcomes, with an optimized design to further improve valve blood flow.

When the aortic valve doesn't close properly (aortic regurgitation) or fails to open fully (aortic stenosis), the heart doesn’t pump blood efficiently and blood flow to the body is reduced. If left untreated, aortic valve disease can lead to heart failure, stroke, blood clots or death. Diseased or damaged heart valves that can't be repaired may be surgically replaced with either mechanical or bioprosthetic (tissue) valves in an open-heart surgical procedure. Bioprosthetic valves like Epic Max are recommended for patients requiring valve replacement who aren't suitable for taking blood-thinning medication.

Epic Max is designed to achieve excellent hemodynamics, or blood flow, and its low-profile frame facilitates potential future transcatheter interventions for patients. This new valve is built on the Epic surgical valve platform, leveraging its long-term performance and durability.  

"The aortic valve is one of the heart valves most commonly impacted by cardiovascular disease, frequently requiring replacement," said Joseph E. Bavaria, M.D., cardiovascular surgery, University of Pennsylvania, "Abbott's Epic Max design optimizes blood flow for patients and has a low profile that makes future cardiac interventions, if necessary, easier."

"With Epic Max, we're accomplishing two important things: First and foremost, we're improving heart valve hemodynamics, which is the purpose of the procedure. Secondly, we're preserving options and ability for patient lifetime disease management, an ever more critical point of consideration in device therapy selection," said Michael Dale, senior vice president of Abbott's structural heart business.

For more information: https://abbo.tt/EpicMaxISI


Related Content

News | Structural Heart

April 9, 2024 — UC Davis Health cardiology team members are among the first in the country to treat patients with ...

Home April 09, 2024
Home
News | Structural Heart

March 25, 2024 — In a groundbreaking medical advancement, three esteemed cardiologists from CLS Health, Dr. Bahaeddin ...

Home March 25, 2024
Home
News | Structural Heart

March 12, 2024 — Medtronic plc, a global leader in healthcare technology, today announced two late-breaking data ...

Home March 12, 2024
Home
News | Structural Heart

February 20, 2024 — As New Jersey’s leading provider of high-quality cardiac procedures and diagnostic testing and an ...

Home February 20, 2024
Home
News | Structural Heart

February 15, 2024 — Abbott announced that the Circulatory System Devices Panel of the Medical Devices Advisory Committee ...

Home February 15, 2024
Home
News | Structural Heart

February 9, 2024 — Physicians in the Smidt Heart Institute at Cedars-Sinai have achieved two significant firsts ...

Home February 09, 2024
Home
News | Structural Heart

January 4, 2024 — Laguna Tech USA, a privately-held medical technology company dedicated to innovations in structural ...

Home January 04, 2024
Home
News | Structural Heart

December 12, 2023 — Think of them as the Energizer Bunnies of the heart, tiny natural batteries that keep this vital ...

Home December 12, 2023
Home
News | Structural Heart

October 31, 2023 — Edwards Lifesciences Corporation announced one-year results from CLASP IID, the first randomized ...

Home October 31, 2023
Home
News | Structural Heart

October 26, 2023 — Abbott announced data from late-breaking presentations showing the impact of its minimally invasive ...

Home October 26, 2023
Home
Subscribe Now